AVISTA PHARMA SOLUTIONS INC has a total of 34 patent applications. It decreased the IP activity by 14.0%. Its first patent ever was published in 2014. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and basic materials chemistry are AVENTIS AGRICULTURE, MEIJI SEIKA PHARMA CO LTD and NOVARTIS ANIMAL HEALTH US INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 15 | |
#2 | WIPO (World Intellectual Property Organization) | 7 | |
#3 | Australia | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Mexico | 2 | |
#6 | Brazil | 1 | |
#7 | Canada | 1 | |
#8 | Japan | 1 | |
#9 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Basic materials chemistry | |
#4 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Speake Jason D | 23 |
#2 | Perales Joe B | 17 |
#3 | Fan Weiming | 13 |
#4 | Pandi Bharathi | 10 |
#5 | Beck Brent Christopher | 8 |
#6 | Rolland Solene Clarisse | 7 |
#7 | Li Keqiang | 5 |
#8 | Moore Iii Joseph A | 5 |
#9 | Adams Jeffrey A | 4 |
#10 | Joe B Perales | 4 |
Publication | Filing date | Title |
---|---|---|
WO2020160074A1 | Synthetic process and novel intermediates | |
WO2020160075A1 | Chemical compounds | |
US2020138811A1 | Sulfonamide derivatives as JAK inhibitors | |
EP3710453A1 | Single enantiomer antiparasitic compounds | |
WO2019245590A1 | Chemical compounds | |
WO2018009751A1 | Antiparasitic compounds | |
WO2017201134A1 | Synthetic process and novel intermediates | |
KR20170102359A | Antiparasitic compound |